Kraig Biocraft Laboratories, Inc. (KBLB)

SEC fundamentals · as filed in 10-Q FY2026, period ended Jun 30, 2026 · updated Oct 29, 2026

Verified against EDGAR
Total Assets
$4.3M
Stockholders' Equity
-$6.8M
Cash & Equivalents
$3.4M
Long-Term Debt
—

as filed in 10-Q FY2026, period ended Jun 30, 2026 · View filings on EDGAR ↗

In its 10-Q for the period ended Jun 30, 2026, Kraig Biocraft Laboratories, Inc. reported net income of -$909,535 and total assets of $4.3M. Every figure below is taken directly from Kraig Biocraft Laboratories, Inc.'s SEC filings: each links to the source document on EDGAR.

Revenue and net income by fiscal year

As reported in each year’s annual filing · USD

Fiscal yearRevenueNet income
FY2025—-$3.6M
FY2024—-$3.4M
FY2023—-$3.0M
FY2022—-$3.8M
FY2021—-$8.0M
FY2020—-$5.0M
FY2019—-$2.9M
FY2018$401,620-$1.2M
FY2017$97,318-$2.3M
FY2016$31,858-$3.1M

Recent SEC filings

Filed by the registrant · newest first · insider forms and holder schedules not included

FormFiledSource
10-QAug 13, 2026on EDGAR ↗
10-QMay 14, 2026on EDGAR ↗
10-KMar 30, 2026on EDGAR ↗
8-KFeb 18, 2026on EDGAR ↗
10-QNov 12, 2025on EDGAR ↗
10-QAug 14, 2025on EDGAR ↗
10-QMay 15, 2025on EDGAR ↗
10-KMar 28, 2025on EDGAR ↗
S-1Feb 7, 2025on EDGAR ↗
8-KJan 21, 2025on EDGAR ↗

All filings on EDGAR ↗

Balance Sheet

as of Jun 30, 2026 · 10-Q

Total Assets$4.3Msource ↗
Stockholders’ Equity-$6.8Msource ↗
Cash & Equivalents$3.4Msource ↗
Long-Term Debt—source ↗

Income Statement

10-Q (quarterly) · period ended Jun 30, 2026

Revenue—source ↗
Net Income-$909,535source ↗
Operating Income-$703,433source ↗
Gross Profit—source ↗
Cost of Revenue—source ↗
R&D Expense$64,369source ↗

Per Share & Cash Flow

10-Q (quarterly) · period ended Jun 30, 2026

EPS (diluted)$0.00source ↗
EPS (basic)$0.00source ↗
Shares Outstanding1.10Bsource ↗
Cash from Operations-$598,695source ↗
Cash from Financing$1.1Msource ↗
Cash from Investing-$28,608source ↗

Restatement history

Point-in-time

3 of 320 annual fact-keys were materially restated between filings: what Kraig Biocraft Laboratories, Inc. first reported differed from what it later filed. We keep every vintage of every annual figure, each keyed to its EDGAR accession.

See each original-vs-restated value, and query any company as of any past date, with the point-in-time API.

Deeper fundamentals

A free API key reaches KBLB’s revenue, margin and free-cash-flow trajectory (newest 3 fiscal years) and its leverage, liquidity and return ratios (newest 4 quarters). Analyst extends those to up to 20 years and 20 quarters, and adds the Piotroski F-score and accruals quality score. As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail, across the whole SEC universe.

Programmatic access

Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.

These fundamentals, as filed
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/KBLB

MCP tool: get_sec_fundamentals ticker=KBLB

The same figures as they were known on any past date
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/KBLB/as-of/YYYY-MM-DD

MCP tool: get_asof_fundamentals ticker=KBLB as_of=YYYY-MM-DD

Fiscal-year trajectory: revenue, margins, free cash flow
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/KBLB/history

MCP tool: get_fundamentals_history ticker=KBLB

Leverage, liquidity, margin and return ratios
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/financial-health/KBLB

MCP tool: get_financial_health ticker=KBLB

Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.